Impact of Polypharmacy, Drug-Related Problems, and Potentially Inappropriate Medications in Geriatric Patients and Its Implications for Bulgaria-Narrative Review and Meta-Analysis.
Bulgaria
drug-related problems
elderly patients
inappropriate prescribing
meta-analysis
polypharmacy
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
07
2021
accepted:
17
01
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Polypharmacy and inappropriate prescribing are overlooked issues in Bulgaria. We aimed at collecting and analyzing global literature on the most prevalent risk factors and investigating what they could reveal about current practice. A systematic narrative review and meta-analysis was conducted on the topic, investigating the prevalence of polypharmacy, odds of potentially inappropriate medications (PIMs) due to polypharmacy, and the likelihood of developing a drug-related problem (DRP) due to PIMs. The results were then related to current demographic statistics to estimate the potential impact on Bulgarian elderly patients. The prevalence of polypharmacy was estimated at 41% in elderly populations. The odds of a potentially inappropriate medication being prescribed were 2.095, with an expected 30.84% of those leading to a DRP. These numbers indicated that the expected Bulgarian elderly with polypharmacy should be 709,676 with 212,903 cases of DRPs. Global polypharmacy rates seem to be on the rise, with an expected increase in DRPs.
Identifiants
pubmed: 35309221
doi: 10.3389/fpubh.2022.743138
pmc: PMC8927684
doi:
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
743138Informations de copyright
Copyright © 2022 Krustev, Milushewa and Tachkov.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Manag Care Spec Pharm. 2019 May;25(5):573-577
pubmed: 31039057
J Nutr Health Aging. 2013 Apr;17(4):399-400
pubmed: 23538666
J Clin Pharm Ther. 2008 Aug;33(4):381-92
pubmed: 18613856
Int J Clin Pharm. 2019 Dec;41(6):1555-1561
pubmed: 31595450
Res Nurs Health. 2008 Feb;31(1):42-51
pubmed: 18163447
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
Epidemiol Rev. 2013;35:75-83
pubmed: 23372025
J Clin Oncol. 2020 Aug 1;38(22):2558-2569
pubmed: 32250717
Expert Rev Clin Pharmacol. 2017 Apr;10(4):345-347
pubmed: 28271722
PLoS Med. 2019 May 8;16(5):e1002798
pubmed: 31067214
Res Social Adm Pharm. 2022 Apr;18(4):2625-2633
pubmed: 33994117
PLoS One. 2014 Aug 19;9(8):e105425
pubmed: 25136981
Ann Emerg Med. 2001 Dec;38(6):666-71
pubmed: 11719747
PLoS One. 2010 Nov 12;5(11):e13977
pubmed: 21103046
Int J Clin Pharm. 2016 Feb;38(1):46-53
pubmed: 26597955
Nurs Clin North Am. 2017 Sep;52(3):457-468
pubmed: 28779826
Eur J Clin Pharmacol. 2015 Oct;71(10):1255-62
pubmed: 26249851
BMC Pharmacol Toxicol. 2016 Aug 21;17(1):38
pubmed: 27544266
Drugs Aging. 2011 Jul 1;28(7):509-18
pubmed: 21721596
Expert Rev Clin Pharmacol. 2020 Jan;13(1):15-22
pubmed: 31790317
Ann Med. 2021 Dec;53(1):17-25
pubmed: 32700579
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):220-228
pubmed: 33026123
BMJ Open. 2016 Apr 04;6(4):e010505
pubmed: 27044582
Int J Clin Pharmacol Ther. 2008 Feb;46(2):72-83
pubmed: 18218287
Age Ageing. 2008 Nov;37(6):673-9
pubmed: 18829684
Acta Diabetol. 2006 Aug;43(2):37-42
pubmed: 16865327